Zafgen Inc (NASDAQ:ZFGN) Shorts Increased By 13.18%

June 29, 2018 - By Alberto Lyles

Zafgen, Inc. (NASDAQ:ZFGN) Corporate Logo

Change of 13.18% for Zafgen Inc (NASDAQ:ZFGN)’s short interest was registered. In June was issued ZFGN’s total 677,600 short interest by FINRA. The 598,700 previous shares are up with 13.18%. Zafgen Inc (NASDAQ:ZFGN) has 171,500 shares average volume. It’ll cost 4 days for ZFGN to restore its previous position. Zafgen Inc’s short interest float is 3.01%.

Ticker’s shares touched $9.98 during the last trading session after 3.96% change.Zafgen, Inc. has 539,372 shares volume, 114.87% up from normal. ZFGN is uptrending and has moved 60.78% since June 29, 2017. The stock outperformed the S&P 500 by 48.21%.

Zafgen, Inc., a biopharmaceutical company, focuses on the development of therapeutics for patients suffering from metabolic diseases comprising type 2 diabetes and obesity.The firm is worth $275.08 million. The companyÂ’s lead product candidate is ZGN-1061, a fumagillin-class MetAP2 inhibitor administered by subcutaneous injection, which is in Phase 1 clinical trial and profiled for its utility in the treatment of metabolic diseases.Currently it has negative earnings.

Zafgen, Inc. (NASDAQ:ZFGN) Ratings Coverage

In total 2 analysts cover Zafgen (NASDAQ:ZFGN). “Buy” rating has 1, “Sell” are 0, while 1 are “Hold”. (NASDAQ:ZFGN) has 50% bullish analysts. 2 are the (NASDAQ:ZFGN)’s ratings reports on Jun 29, 2018 according to StockzIntelligence Inc.

For more Zafgen, Inc. (NASDAQ:ZFGN) news published briefly go to: Globenewswire.com, Benzinga.com, Seekingalpha.com, Nasdaq.com or Benzinga.com. The titles are as follows: “Zafgen Announces Proposed Offering of Common Stock” published on June 27, 2018, “48 Biggest Movers From Yesterday” on June 29, 2018, “Zafgen: 3 Key Takeaways From ADA Abstracts” with a publish date: June 26, 2018, “Zafgen Announces Positive Full Results in Phase 2 Proof-of-Concept Trial of ZGN-1061 in Patients with Difficult-to …” and the last “Benzinga’s Daily Biotech Pulse: Eli Lilly, Edge Therapeutics, BioXcel Report Positive Trial Results, 4 Stocks Debut” with publication date: June 28, 2018.

Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our FREE daily email newsletter.




Free Email Newsletter

Enter your email address below to get the latest news and analysts' ratings for your stocks with our free daily email newsletter: